US EditionKodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases
- Kodiak Sciences Inc. Announced on May 1, 2025, that it will present seven scientific research programs at the ARVO 2025 meeting in Salt Lake City, Utah, from May 4-8.
- Kodiak developed its ABC platform to create innovative therapies targeting complex multifactorial retinal diseases, including ocular inflammatory disease and geographic atrophy, which have high unmet needs.
- The company is advancing investigational medicines such as KSI-101, a bispecific protein in Phase 1b for macular edema secondary to inflammation, and KSI-501, a bispecific antibody biopolymer conjugate for geographic atrophy and wet AMD.
- Preliminary findings from the APEX study indicate that KSI-101 effectively reduces macular swelling and enhances visual acuity across all tested doses, whereas existing treatments for geographic atrophy involve frequent intravitreal injections and provide limited benefit.
- Kodiak's research highlights the ABC platform's potential to develop multifunctional, high drug-antibody-ratio therapeutics for retinal diseases, though clinical and economic risks remain, with no obligation to update forward-looking statements.
42 Articles
42 Articles
The Billings Gazette
Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases
PALO ALTO, Calif., May 1, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that seven scientific presentations on its research programs…
Harnessing Artificial Intelligence to Transform Vision Research
Salt Lake City, Utah — Artificial Intelligence (AI) is reshaping the way we comprehend, detect and treat eye conditions, bringing new hope to millions worldwide. During the upcoming week (May 4 - 8) at the 2025 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Salt Lake City, Utah, researchers will share breakthroughs on how AI is influencing the future of eye and vision health research and patient care, from en
Coverage Details
Bias Distribution
- 91% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
